Edward A. Stadtmauer

36.1k total citations · 6 hit papers
331 papers, 14.0k citations indexed

About

Edward A. Stadtmauer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Edward A. Stadtmauer has authored 331 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Hematology, 156 papers in Oncology and 94 papers in Molecular Biology. Recurrent topics in Edward A. Stadtmauer's work include Multiple Myeloma Research and Treatments (145 papers), Hematopoietic Stem Cell Transplantation (83 papers) and Cancer Treatment and Pharmacology (47 papers). Edward A. Stadtmauer is often cited by papers focused on Multiple Myeloma Research and Treatments (145 papers), Hematopoietic Stem Cell Transplantation (83 papers) and Cancer Treatment and Pharmacology (47 papers). Edward A. Stadtmauer collaborates with scholars based in United States, Canada and Netherlands. Edward A. Stadtmauer's co-authors include Dan T. Vogl, David Porter, Donald E. Tsai, Stephen J. Schuster, Selina M. Luger, Sagar Lonial, Alison W. Loren, Rubén Niesvizky, Adam D. Cohen and D Delia and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Edward A. Stadtmauer

323 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

2007 925 citations Donna M. Weber, Rubén Niesvizky et al. profile →
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 654 citations Edward A. Stadtmauer et al. profile →
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

2009 579 citations Edward A. Stadtmauer et al. Blood profile →
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Amrita Krishnan, Edward A. Stadtmauer et al. profile →
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

1993 533 citations Edward A. Stadtmauer et al. Blood profile →
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Wei‐Ting Hwang et al. profile →

Peers

Countries citing papers authored by Edward A. Stadtmauer

Since Specialization

Citations

This map shows the geographic impact of Edward A. Stadtmauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. Stadtmauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. Stadtmauer more than expected).

Fields of papers citing papers by Edward A. Stadtmauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. Stadtmauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. Stadtmauer. The network helps show where Edward A. Stadtmauer may publish in the future.

Co-authorship network of co-authors of Edward A. Stadtmauer

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. Stadtmauer. A scholar is included among the top collaborators of Edward A. Stadtmauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. Stadtmauer. Edward A. Stadtmauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma 2025 ·Blood Advances ·(unknown), Harper Hubbeling, Kang Yu, (unknown), Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, (unknown), Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Alfred L. Garfall, Sandra P. Susanibar-Adaniya	0
2	Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma 2024 ·Bone Marrow Transplantation ·(unknown), (unknown), Jonathan Sussman, Alfred L. Garfall, Adam D. Cohen, (unknown), Sandra P. Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer	2
3	Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial 2024 ·Transplantation and Cellular Therapy ·Ehsan Malek, (unknown), Leland Metheny, Pingfu Fu, Gen Li, Parameswaran Hari, Yvonne A. Efebera, Natalie S. Callander, Muzaffar H. Qazilbash, Sergio Giralt, Amrita Krishnan, Edward A. Stadtmauer, Hillard M. Lazarus	1
4	Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells 2023 ·Transplantation and Cellular Therapy ·Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, James N. Gerson, Stephen J. Schuster, Stefan K. Barta, Elise A. Chong, (unknown), Elizabeth Weber, (unknown), (unknown), Alfred L. Garfall, Edward A. Stadtmauer, Noelle V. Frey, David L. Porter	3
5	Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia 2022 ·Blood Advances ·Andrew Matthews, Alexander E. Perl, Selina M. Luger, Alison W. Loren, Saar Gill, David L. Porter, Daria V. Babushok, Ivan Maillard, Martin Carroll, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Vikram R. Paralkar, (unknown), Wei‐Ting Hwang, David M. Margolis, Keith W. Pratz	53
6	Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies 2022 ·Transplantation and Cellular Therapy ·(unknown), Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, (unknown), (unknown), Jacqueline Smith, (unknown), Alexis Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey	2
7	A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial 2022 ·Transplantation and Cellular Therapy ·Qaiser Bashir, Taiga Nishihori, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina, Claudio Anasetti, Claudio G. Brunstein, Peter Dawson, Yvonne A. Efebera, Cristina Gasparetto, Nancy L. Geller, Sergio Giralt, Aric C. Hall, John Koreth, Philip L. McCarthy, Emma Scott, Edward A. Stadtmauer, David H. Vesole, Parameswaran Hari	5
8	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? 2022 ·British Journal of Haematology ·Mouhamed Yazan Abou‐Ismail, Raphael Fraser, (unknown), Leland Metheny, (unknown), Kwang Woo Ahn, Neel S. Bhatt, Hillard M. Lazarus, Marcos de Lima, Najla El Jurdi, Peiman Hematti, Amer Beitinjaneh, Taiga Nishihori, Sherif M. Badawy, Akshay Sharma, Marcelo C. Pasquini, Bipin N. Savani, Mohamed L. Sorror, Edward A. Stadtmauer, Saurabh Chhabra	1
9	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma 2021 ·Clinical Cancer Research ·(unknown), Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, Russell Maxwell, W. Tristram Arscott, Amit Maity, Joshua Jones, John P. Plastaras, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, Michael C. Milone, Ima Paydar	23
10	Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation 2020 ·Blood ·Brian D. Friend, Larisa Broglie, Brent R. Logan, Caitrin Fretham, Gary J. Schiller, Bipin N. Savani, Edward A. Stadtmauer, Saurabh Chhabra, Marcelo C. Pasquini, Monica S. Thakar, Mohamed L. Sorror	3
11	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling 2019 ·Biology of Blood and Marrow Transplantation ·Sarah A. Holstein, Zaid Al‐Kadhimi, Luciano J. Costa, Theresa Hahn, Parameswaran Hari, Jens Hillengaß, Allison P. Jacob, Nikhil C. Munshi, Stefania Oliva, Marcelo C. Pasquini, Qian Shi, Edward A. Stadtmauer, (unknown), Philip L. McCarthy	12
12	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study 2015 ·The Lancet Haematology ·Scott F. Huntington, Brendan M. Weiss, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Patricia Mangan, Jalpa A. Doshi, Edward A. Stadtmauer	165
13	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma 2009 ·European Journal Of Haematology ·Edward A. Stadtmauer, Donna M. Weber, Rubén Niesvizky, Andrew Belch, (unknown), Jesús F. San Miguel, Thierry Façon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis, Robert Knight, Meletios Α. Dimopoulos	82
14	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia 2008 ·Clinical Cancer Research ·Donald E. Tsai, Selina M. Luger, Charalambos Andreadis, Dan T. Vogl, (unknown), (unknown), Ami Goradia, Alison W. Loren, Alexander E. Perl, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, James E. Thompson, Cezary Swider, Adam Bagg, Anthony R. Mato, Martin Carroll	29
15	Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation 2003 ·Journal of Hematotherapy & Stem Cell Research ·John F. Gerecitano, Clarissa Mathias, Rosemarie Mick, Kathleen M. Duffy, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Donald E. Tsai, Sunita D. Nasta, Jesse A. Berlin, (unknown), Katherine A. High, David L. Porter	4
16	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90–Labeled Anti-CD22 Monoclonal Antibody 2003 ·Clinical Lymphoma ·Donald E. Tsai, Ivan Maillard, Stephen J. Schuster, Sunita D. Nasta, David L. Porter, Thomas R. Klumpp, David M. Goldenberg, Selina M. Luger, Abass Alavi, Robert M. Sharkey, (unknown), Edward A. Stadtmauer	7
17	Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy 2002 ·Annals of Hematology ·Ronald J. Buckanovich, (unknown), Carrie Tompkins Stricker, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Kathleen M. Duffy, Donald E. Tsai, Amy A. Pruitt, David L. Porter	43
18	High-Dose Chemotherapy and Stem Cell Support for Breast Cancer 2002 ·Drugs & Aging ·(unknown), Steven Stein, Edward A. Stadtmauer	4
19	Soluble Interleukin-2 Receptor Concentration As a Biochemical Indicator for Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation 2000 ·Journal of Hematotherapy & Stem Cell Research ·Clarissa Mathias, Rosemarie Mick, Stephen Grupp, Kathleen M. Duffy, Frank Harris, Ginna G. Laport, Edward A. Stadtmauer, Selina M. Luger, (unknown), Mariusz A. Wasik, David Porter	26
20	Guidelines for Prophylactic Platelet Transfusions: Need for a Concurrent Outcomes Management System 1992 ·QRB - Quality Review Bulletin ·David J. Shulkin, Kevin R. Fox, Edward A. Stadtmauer	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact